EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSG00000135766
Gene: EGLN1
Gene Synonyms: C1ORF12,HIFPH2,PHD2,SM-20,ZMYND6
2 APIs:
4 Enzyme and pathways 8 Cross references
239 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSG00000269858
Gene: EGLN2
Gene Synonyms: HIFPH1,PHD1
1 APIs:
4 Enzyme and pathways 7 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSG00000129521
Gene: EGLN3
Gene Synonyms: HIFPH3,PHD3
1 APIs:
4 Enzyme and pathways 7 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Elastase, Neutrophil Expressed

Ensembl ID : ENSG00000197561
Gene: ELANE
Gene Synonyms: ELA2,HLE,HNE,NE,PMN-E
2 APIs:
13 Enzyme and pathways 9 Cross references
91 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelial Pas Domain Protein 1

Ensembl ID : ENSG00000116016
Gene: EPAS1
Gene Synonyms: BHLHE73,HIF2A,HLF,MOP2,PASD2
1 APIs:
18 Enzyme and pathways 8 Cross references
225 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelin Converting Enzyme 1

Ensembl ID : ENSG00000117298
Gene: ECE1
Gene Synonyms: ECE
1 APIs:
5 Enzyme and pathways 8 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelin Receptor Type A

Ensembl ID : ENSG00000151617
Gene: EDNRA
Gene Synonyms: ET-A,ETA-R,HET-AR
9 APIs:
7 Enzyme and pathways 8 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelin Receptor Type B

Ensembl ID : ENSG00000136160
Gene: EDNRB
Gene Synonyms: ETB,HSCR,HSCR2
4 APIs:
7 Enzyme and pathways 8 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSG00000106462
Gene: EZH2
Gene Synonyms: ENX-1,EZH1,KMT6,KMT6A
2 APIs:
27 Enzyme and pathways 9 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epidermal Growth Factor Receptor

Ensembl ID : ENSG00000146648
Gene: EGFR
Gene Synonyms: ERBB,ERBB1,ERRP
73 APIs:
71 Enzyme and pathways 9 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epoxide Hydrolase 2

Ensembl ID : ENSG00000120915
Gene: EPHX2
Gene Synonyms: ABHD20,SEH
2 APIs:
10 Enzyme and pathways 8 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSG00000141736
Gene: ERBB2
Gene Synonyms: C-ERB-2,C-ERB2,CD340,HER-2,HER2,MLN-19,NEU,NGL,P185(ERBB2)
39 APIs:
52 Enzyme and pathways 9 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).